Skip to main navigation Skip to search Skip to main content

Performance of the China-CLIF framework in acute-on-chronic liver failure: a multicohort study across all aetiologies

  • The CANONIC, PREDICT, ACLARA Study Group, Chinese Group on the Study of Severe Hepatitis B (COSSH)
  • Zhejiang University
  • The First Affiliated Hospital of Soochow University
  • Hainan Medical University
  • Central South University
  • Fudan University
  • The First Affiliated Hospital of Xi’an Jiaotong University
  • Anhui Medical University
  • European Foundation for the Study of Chronic Liver Failure (EF CLIF)
  • General Hospital of People's Liberation Army
  • Hangzhou Medical College
  • Huazhong University of Science and Technology
  • Wenzhou Medical University
  • Imperial College London
  • Pacific Care Home
  • Nanchang University
  • Sir Run Run Shaw Hospital
  • Nanfang Hospital
  • Taizhou Hospital
  • University of Padua
  • University College London
  • The Third Affiliated Hospital of Sun Yat-sen University
  • Capital Medical University
  • Zhejiang University-University of Toronto Joint Institute of Genetics and Genomic Medicine
  • Universidade de São Paulo
  • University of Münster
  • Université Paris Cité
  • Department of Hepatobiliopancreatic Surgery

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Background Acute-on-chronic liver failure (ACLF) of various aetiologies is a complex syndrome with high short-term mortality and significant global burden. Objective To explore easily applicable diagnostic criteria and an accurate prognostic score for ACLF. Design Clinical data from 5288 patients (after exclusions from 7388 screened) with acute deterioration of chronic liver disease across various aetiologies were used to evaluate the performance of European Chronic Liver Failure (CLIF) and Chinese Group on the Study of Severe Hepatitis B (COSSH) criteria. Three non-Asian cohorts were performed to validate the results. Results CLIF criteria categorised 844 patients as ACLF (28-day/90-day liver transplantation (LT)-free mortality: 40.7%/57.0%; 321 with non-hepatitis B virus (HBV) aetiology, 523 with HBV aetiology), while COSSH criteria categorised 2038 patients as ACLF (mortality: 27.3%/41.0%; 602 with non-HBV aetiology, 1436 with HBV aetiology). COSSH criteria identified 22.6% (1194/5288) more patients (mortality: 19.1%/31.4%) compared with CLIF criteria, including 14.2% non-HBV patients (mortality: 15.9%/33.3%). COSSH criteria produced a more reasonable epidemiological pyramid-like distribution across severity grades (grades 1–3: 63.4%/27.5%/9.1% vs CLIF’s grades 1–3: 25.8%/56.3%/17.9%). COSSH-ACLF II score showed the highest predictive values for 28-day/90-day LT-free mortality in both cirrhotic and all ACLF patients with various aetiologies, outperforming the CLIF-C ACLF and other scores. The comparable performance of China-CLIFs (renamed from COSSH-ACLFs) was validated in three non-Asian cohorts. Conclusions This study evaluated the broader applicability of the China-CLIF framework across diverse aetiologies and varying severity levels of ACLF. These findings may provide a valuable foundation for harmonising ACLF diagnostic and prognostic system.

Original languageEnglish
Pages (from-to)131-146
Number of pages16
JournalGut
Volume75
Issue number1
DOIs
StatePublished - 1 Jan 2026
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • HEPATITIS B
  • LIVER CIRRHOSIS
  • LIVER FAILURE

Fingerprint

Dive into the research topics of 'Performance of the China-CLIF framework in acute-on-chronic liver failure: a multicohort study across all aetiologies'. Together they form a unique fingerprint.

Cite this